The Great Composites Ride to JEC 2022 for Mind

Fluency Marketing Managing Director, Gemma Smith, and R-Tech Materials Director of Composites Testing, Geraint Havard, co- hosts of the Material Evolution podcast, will be taking on the challenge of cycling from London to Paris for JEC World in March 2022, whilst raising vital funds for the mental health charity, Mind.

Mind provide advice and support to empower anyone who experiences a mental health problem. They campaign to improve mental health services, raise awareness and promote understanding.

Mind is a charity which both Gemma and Geraint are passionate about and have supported over previous years. They’re hoping the industry will get behind them and help raise a magnificent £10,000 for the 550km ride which they are hoping to complete over 3 days, in less than 8 weeks’ time!

When asked about the challenge, Gemma Smith said “Mind is a charity that is close to my heart, and I have previously taken part in the London Marathon twice to raise them funds. I have also held many live events to raise funds for the charity, but this is my greatest fundraising goal yet, and I’m excited to take on this challenge. I can’t think of a better person to take on the challenge with and am really pleased Geraint has agreed to tolerate me for 3 days on a bike, just to help Mind.”

Geraint Havard said “I am delighted to support Gemma on this ride. The longest I have ridden a bike for in the past is probably 2 hours, so to do 3 days straight riding will be a huge challenge, but one we both relish. I’m not sure how much energy we will have left for JEC once we finish though! I have always felt that we need more mental health support in this country and the covid crisis has only worsened the situation. Because of this, I can’t think of a better charity to do this in aid of than Mind. ”

The Material Evolution duo will appreciate any support you can give, from sharing their efforts on social media, cheering them on along their route or donating. https://www.justgiving.com/fundraising/londontojec

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”